Evidence map›Paper›PMID 35952979›Full record

ArticleEndocrinology2022

Disruption of Growth Hormone Receptor in Adipocytes Improves Insulin Sensitivity and Lifespan in Mice.

Edward O List, Darlene E Berryman, Julie Slyby, Silvana Duran-Ortiz, Kevin Funk, Elise S Bisset, Susan E Howlett, John J Kopchick

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Growth hormone receptor gene disruption.Vitamins and hormones · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Edward O ListEdison Biotechnology Institute, Ohio University, Athens, Ohio 45701, USA.ORCID 0000-0002-8230-6331
Darlene E BerrymanEdison Biotechnology Institute, Ohio University, Athens, Ohio 45701, USA.
Julie SlybyEdison Biotechnology Institute, Ohio University, Athens, Ohio 45701, USA.
Silvana Duran-OrtizEdison Biotechnology Institute, Ohio University, Athens, Ohio 45701, USA.
Kevin FunkEdison Biotechnology Institute, Ohio University, Athens, Ohio 45701, USA.
Elise S BissetDepartment of Pharmacology Dalhousie University Halifax, Halifax , Nova Scotia , Canada.
Susan E HowlettDepartment of Pharmacology Dalhousie University Halifax, Halifax , Nova Scotia , Canada.
John J KopchickEdison Biotechnology Institute, Ohio University, Athens, Ohio 45701, USA.
Biotechnology Institute · USDalhousie University · CA

Funding

Modulating Growth Hormone Action as a Target for Improved Health and LongevityR01AG059779 · NIA · OHIO UNIVERSITY ATHENS · PI John Joseph Kopchick · 2018 to 2026
$4.7M
NIA NIH HHS R01 AG059779
6 · The paper itself

Abstract

Growth hormone receptor knockout (GHRKO) mice have been used for 25 years to uncover some of the many actions of growth hormone (GH). Since they are extremely long-lived with enhanced insulin sensitivity and protected from multiple age-related diseases, they are often used to study healthy aging. To determine the effect that adipose tissue has on the GHRKO phenotype, our laboratory recently created and characterized adipocyte-specific GHRKO (AdGHRKO) mice, which have increased adiposity but appear healthy with enhanced insulin sensitivity. To test the hypothesis that removal of GH action in adipocytes might partially replicate the increased lifespan and healthspan observed in global GHRKO mice, we assessed adiposity, cytokines/adipokines, glucose homeostasis, frailty, and lifespan in aging AdGHRKO mice of both sexes. Our results show that disrupting the GH receptor gene in adipocytes improved insulin sensitivity at advanced age and increased lifespan in male AdGHRKO mice. AdGHRKO mice also exhibited increased fat mass, reduced circulating levels of insulin, c-peptide, adiponectin, resistin, and improved frailty scores with increased grip strength at advanced ages. Comparison of published mean lifespan data from GHRKO mice to that from AdGHRKO and muscle-specific GHRKO mice suggests that approximately 23% of lifespan extension in male GHRKO is due to GHR disruption in adipocytes vs approximately 19% in muscle. Females benefited less from GHR disruption in these 2 tissues with approximately 19% and approximately 0%, respectively. These data indicate that removal of GH's action, even in a single tissue, is sufficient for observable health benefits that promote long-term health, reduce frailty, and increase longevity.

Indexed as

FrailtyInsulin ResistanceAdipocytesAnimalsFemaleGrowth HormoneInsulin-Like Growth Factor ILongevityMaleMiceMice, KnockoutReceptors, SomatotropinGrowth HormoneInsulin-Like Growth Factor IReceptors, Somatotropinadipocyteadipose tissuegrowth hormonegrowth hormone receptortissue-specific knockout

Identifiers

PMID35952979
PMCPMC9467438
OpenAlexW4290999918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.